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Accurate and sensitive imaging biomarkers are required to study the progression of white matter 
(WM) microglial activation in neurodegenerative diseases in vivo. The translocator protein (TSPO) 
is considered a sensitive target for imaging microglial activation with positron emission 
tomography (PET). This study aimed to test the ability of TSPO to detect WM microglial activation 
marked by major histocompatibility complex class II (MHCII) molecules in rat models of 
prodromal Alzheimer’s disease and acute subcortical stroke.  
Methods 
Fischer 344 wild-type (n = 12) and TgAPP21 (n = 11) rats were imaged with [18F]FEPPA PET 
and MRI to investigate TSPO tracer uptake in the corpus callosum. Wild-type rats subsequently 
received an endothelin-1 (ET1)-induced subcortical stroke and were imaged at days 7 and 28 post-
stroke before immunohistochemistry of TSPO, GFAP for astrocytes, iNOS for microglia releasing 
toxic nitrous oxide, and the MHCII rat antigen, OX6.  
Results 
[18F]FEPPA-PET findings that TSPO expression was not increased in WM of TgAPP21 rats and 
was only increased in the infarct and proximal WM were confirmed by immunohistochemistry 
(infarct TSPO cells/mm2: day 7 = 555 ± 181; day 28 = 307 ± 153; proximal WMTSPO cells/mm2: 
day 7 = 113 ± 93; day 28 = 5 ± 7). TSPO and iNOS were not able to detect the chronic WM 
microglial activation that was detected with MHCII in the contralateral corpus callosum (day 28 




Within the regions and groups investigated, TSPO was only expressed in the stroke-induced insult 
and proximal tissue, and therefore was unable to detect remote and non-insult-related chronically 
activated microglia overexpressing MHCII in WM.  
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Accurate and sensitive biomarkers are required to study the progression of inflammation in 
neurological diseases. To image white matter inflammation in living subjects, researchers can 
produce radioactive molecules that bind to proteins in the body that serve as markers of 
inflammation, inject them into the subject, then image them with positron emission tomography 
(PET). Our group set out to investigate whether a protein known as the translocator protein can be 
detected, in living subjects, in a type of white matter inflammation that we previously associated 
with Alzheimer’s disease and deep stroke and can currently only be imaged after death. We 
hypothesized that the translocator protein expression can be detected in rats with Alzheimer’s 
Disease at the white matter and in rats with deep stroke at white matter that was distant from the 
stroke.  
Methods 
Rats that were non-genetically modified (n = 12) and genetically modified to express a protein 
associated with Alzheimer’s Disease (n = 11) were injected with the radioactive molecule 
[18F]FEPPA to image the translocator protein using PET. After initial assessment of white matter 
inflammation, the non-genetically modified rats received a deep stroke and were imaged again at 
days 7 and 28 post-stroke. The rats were sacrificed to investigate their expression of the 







[18F]FEPPA positron emission tomography only detected inflammation in the stroke region of rats 
that received the deep stroke; the distant white matter inflammation we wanted to image was not 
detected.  Inflammation was detected in distant white matter using post-mortem microscopy of the 
inflammatory molecule OX6, but it was not detectable using the translocator protein, irrespective 
of the binding molecule used.  
Conclusion 
Within the regions and groups investigated, the translocator protein was only able to detect 
inflammation near the stroke region, and therefore was not able to detect the distant and non-
injury-related yet pathologically important white matter inflammation that we wanted to detect. 
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Chapter 1: Introduction 
Chronic white matter (WM) inflammation can be observed in subcortical stroke, traumatic brain 
injury, schizophrenia, and Alzhiemer’s Disease (AD) [1–4]. In particular, chronic WM 
microglial activation marked by major histocompatibility complex class II (MHCII) molecules is 
believed to play an early neurotoxic role [5]. To further our understanding, develop therapeutic 
approaches, and aid early diagnosis, there is a need to quantify WM MHCII microglial activation  
in living people. Still, there is no established method for the in vivo quantification of WM 
MHCII microglial activation. In this thesis, the objective was to image chronic WM MHCII 
microglial activation in vivo using translocator protein positron emission tomography (TSPO-
PET) in rat models of AD and subcortical stroke. The following introduction presents evidence 
for why MHCII microglial activation may play a neurotoxic role in AD and subcortical stroke 
and background for TSPO and PET. 
1.1 White Matter (WM) Importance and Function 
In vertebrates, brain WM is an important constituent of neuronal networks, which are widely 
accepted as responsible for motor movement, thoughts, and meaningful behavior [6]. An 
individual neuron in the networks is composed of a cell body, axons that protrude from the cell 
body, and dendrites. In the central nervous system (CNS), oligodendrocytes support and wrap 
axons with multiple layers of myelin. Myelinated axons appear white and therefore form the 
structure known as WM. By wrapping the entire length of axons except for interspaced nodes with 
myelin, nerve impulses made up of sodium and potassium ions are forced to occur only at the 
nodes instead of throughout the entire axon. This is known as saltatory conduction and it makes 
neuron-neuron communication more rapid by increasing the charge difference along the axonal 




reduction in conduction velocity, nerve impulses become less temporally predictable, and nerve 
impulses often do not lead to downstream activation [7]. As myelin is the main component of white 
matter, healthy WM is essential for healthy cognitive and motor function. 
1.2 Inflammation and Microglial Activation 
In general, inflammation can be acute or chronic after an injury, pathogen, or autoimmune 
response. Acute inflammation occurs in regions that have recently been exposed to an appropriate 
stimulus, and regions outside the CNS experiencing acute inflammation are influxed with fluid to 
cause swelling also known as edema. This may cause pain and loss of function by stressing nearby 
neuroreceptors, and an increased blood flow may cause a red appearance and a feeling of heat [8]. 
In contrast, chronic inflammation occurs late after a stimulus, and regions outside the CNS 
experiencing chronic inflammation are usually only associated with changes in signalling 
molecules, although the molecules are different than those in acute inflammation, and white blood 
cells such as macrophages [8].  
Macrophages and cells with similar lineages, such as microglia in the CNS, are often 
investigated to study the state of inflammation. The term macrophage is often used to refer to a 
type of peripheral cell that is able to remove pathogens, dying cells, or debris by releasing reactive 
oxygen species, phagocytosis, and enzyme-mediated digestion [9]. That said, macrophages also 
seem to be necessary for the healing processes of re-epithelialization, collagen deposition, and 
angiogenesis [10].  
Inflammation in the CNS, also known as neuroinflammation, is similar to inflammation 
outside the CNS with respect to the details discussed above. Exceptions include that (i) redness, 
heat, and pain are not usually reported along with acute neuroinflammation and (ii) a healthy CNS 





Microglia are substantial contributors to the overall health of the brain because of their importance 
as the main immune cells of the CNS and prevalence; microglia comprise 10% of the CNS cellular 
population [11]. Although microglia are often termed ‘resting’ when they are in their inactive state, 
inactive microglia are usually mobilizing their appendages to survey their microenvironment [12]. 
Upon detection of a variety of cues, microglia become activated and take on roles that may be 
neuroprotective or neurotoxic. 
Based on whether activated microglia play a neuroprotective and anti-inflammatory role 
or a neurotoxic and pro-inflammatory role, they may be classified as M2 or M1, respectively [13]. 
Dichotomization is an oversimplification following investigation of a variety of molecules, but it 
may be practical in guiding non-specific anti-inflammatory therapy as microglia may play a variety 
of roles depending on the molecules that they are expressing. Molecular markers in rats that mark 
M1 microglia include iNOS, MHCII, and CD68 while those that mark M2 microglia include Arg1, 
Ym1, and CD206 [14]. Examples of the neuroprotective roles that M2 microglia contribute to are 
myelin repair, the removal of cellular and protein debris, and the secretion of neurotrophic factors 
that prevent neural injury [13]. On the other hand, M1 microglia tend to release cytokines that 
recruit more microglia whilst releasing proteases, reactive nitrogen species, and oxygen species 
[13].  
1.2.2 Astrocytes 
Astrocytes are a major cell type in the CNS, and although they are often known for their supportive 
roles, astrocytes can play a role in inflammatory processes [15]. Supportive roles that astrocytes 
play include maintenance of synapses, providing energetic metabolites to neurons, forming a key 




recycling toxic waste products such as ammonia [15]. Like microglia, astrocytes termed A2 exhibit 
neuroprotective and anti-inflammatory functions such as the support of BBB repair and formation 
of an astrocytic barrier to restrict the infiltration of other white blood cells whilst releasing 
signalling molecules that downregulate inflammation [16]. Astrocytes can be termed as A1 when 
they exhibit neurotoxic and pro-inflammatory functions such as the release of neurotoxic amounts 
of glutamate whilst releasing signalling molecules that upregulate inflammation [16]. In any case, 
inflammatory activation of astrocytes can be marked by overexpression of the glial acid fibrillary 
protein (GFAP) [17]. An important distinction given our interest in WM is that astrocytes are 
called fibrous or protoplasmic astrocytes based on their appearance and whether they are expressed 
in WM or grey matter, respectively [17]. 
1.3 Subcortical Stroke 
To contextualize subcortical stroke, it is important to first discuss strokes in general. In the context 
of the brain, a stroke is when a brain region has insufficient vascular perfusion to survive [18]. 
Strokes are usually divided into hemorrhagic and ischemic stroke based on whether the stroke is 
caused by a vascular rupture or occlusion, respectively, as these two require substantially different 
treatments [18]. Additionally, treatment options in ischemic stroke depend on the time since onset, 
which has led to the classification of stroke into acute (< 24 hours), subacute (24 hours to 5 days), 
and chronic (> 5 days) [19]. Alternatively, strokes may be distinguished based on their location, 
and therefore affected brain functions, into cortical and subcortical strokes [20]. 
1.3.1 Subcortical Stroke Etiology 
According to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, 
subcortical strokes may be caused by small-vessel disease, large-vessel disease, or embolism [18]. 




than 15 mm in diameter [18]. On the other hand, subcortical strokes associated with small-vessel 
disease can present as lacunar strokes that are less than 15 mm in diameter and are not caused by 
embolism or arterial stenosis [18]. In general, lacunar stroke is associated with, and thought to 
occur by, diffuse abnormality of small vessel endothelial cells, slight increases of BBB 
permeability, and leakage of substances from the blood that are considered toxic to the brain [21]. 
Despite evidence for the role of endothelial cells, why lacunar stroke could have a sudden 
symptomatic onset remains under investigation [21].  
1.3.2 Stroke Molecular Changes 
Although decreased perfusion triggers the onset of stroke, it is important to realize that there are 
other downstream toxic effects. In particular, insufficient perfusion in stroke hinders the ability of 
the affected region to keep up with the demand for energy from adenosine triphosphate, thereby 
initiating several toxic processes [22]. These include acidosis as the body tries to generate 
adenosine triphosphate by lactic acid metabolism, glutamate excitotoxicity by induction of calcium 
and sodium influx and the ensuing edema, production of reactive oxygen species, reactive nitrogen 
species, lipases, proteases, and nucleases, and activation of glial cells, disruption of the BBB, and 
infiltration of peripheral leukocytes [22]. 
1.3.3 Stroke Infarct Core and Penumbra 
The concept of infarct core and penumbra is important in stroke and is also relevant in subcortical 
stroke. The infarct core is a region in the center of the stroke site that is non-functional and does 
not have enough perfusion to survive. On the other hand, the infarct penumbra is non-functional 
but, although it has a perfusion deficiency, it can be salvaged using thrombolytic therapy [23]. 
Salvaging the penumbra improves cognitive and functional outcome in people who experience a 




is the same for the detection of an infarct core and penumbra within 4.5 hours, which is 20-60% 
depending on perfusion thresholds [24]. 
Rodent studies have shown that the neuroinflammatory cell composition differs between 
the infarct core and penumbra, but this difference seems to invert with time. Histological 
differentiation of the infarct core and penumbra may be accomplished using microtube-associated 
protein 2 (MAP2) immunohistochemistry signal, which is high in healthy tissue, medium in the 
infarct penumbra, and low to nonexistent in the infarct core [25,26]. By using multi-label 
immunofluorescence of neuroinflammatory cells and MAP2 in rodents, a recent study has been 
able to describe the early post-stroke relationship between the infarct core and penumbra with 
microglia and astrocytes [27]. In the 2-day re-perfused penumbra, activated astrocytes make a 
barrier that surrounds the activated M2 microglia-dense infarct core [27]. At later timepoints, 
activated astrocytes can be mostly found in the center of the infarct while M1 activated microglia 
tend to be in peripheral regions and remote regions [26–30].  
1.3.4 WM Microglial Activation and Disease in Subcortical Stroke 
Before describing WM microglial activation, it is necessary to describe the potentially related 
measurements of WM integrity. WM integrity can be measured with diffusion tensor imaging 
(DTI), as described below, but the measurements can often have more than one biological 
interpretation. As one of many magnetic resonance imaging (MRI) techniques, DTI quantifies 
the rate and directionality of water diffusion. The rate and directionality are represented in the 
parameters mean diffusivity and fractional anisotropy, respectively. Fractional anisotropy (FA) 
in particular can be related to WM integrity, with high FA reflecting relatively unimpeded 
diffusion parallel to the axonal fibers and restricted diffusion perpendicular to the direction of the 




decrease in myelin content, axon count, and increase in CSF, while the decrease of both FA and 
mean diffusivity has been interpreted as gliosis, tract incoherence, and a decrease in axon count 
[31]. Although DTI alone cannot specifically measure myelin content or axon count, changes in 
FA and mean diffusivity can be interpreted in terms of WM integrity.  
Clinical studies of WM disease after subcortical stroke have found that remote regions of 
the directly affected tract have increased microglial activation and reduced integrity, and that 
remote WM of tracts that were not directly affected have a late reduction in integrity. In particular, 
one study showed that remote regions of the directly affected pyramidal tract, which is the major 
WM tract related to motor function, had increased microglial activation and decreased WM 
integrity, as indicated by FA, throughout the whole tract at <3 weeks and at 6 months post-stroke 
[1]. In that study, microglial activation was measured in vivo by using PET to take advantage of 
the increased microglial and astrocyte expression of TSPO. As subcortical strokes outside the non-
pyramidal tract had no effect on pyramidal tract microglial activation and integrity, it appeared 
that the WM tract had to be directly affected by a subcortical stroke for changes in integrity and 
microglial activation to be detectable by 6 months after stroke in humans. In contrast, the same 
group found late changes in integrity of a WM region that was not directly affected; the 
transcallosal motor fiber FA was normal within 20 days but decreased by 6 months after 
subcortical stroke in the pyramidal tract and not after subcortical stroke outside the pyramidal tract 
[32]. Overall, this data suggests that subcortical stroke in the pyramidal tract leads to early 
disintegration of directly connected WM and late disintegration of functionally connected WM. 
Whether the functionally connected WM experiences microglial activation and whether these 





Leukoaraiosis, also identified as WM hyperintensities using T2-weighted or fluid-
attenuated inversion recovery (FLAIR) MRI, is associated with subcortical lacunar stroke, but not 
with large subcortical strokes [33]. WM hyperintensities usually refer to leukoaraiosis of presumed 
vascular etiology, but WM hyperintensities increase with normal aging and may appear due to a 
variety of pathologies [33,34]. For example, WM hyperintensities have been histologically 
attributed to various changes such as microglial and astrocyte activation, endothelial activation, 
edema, vacuolization, demyelination, axonal loss, and the presence of proteins including 
fibrinogen, immunoglobulins, and thrombomodulin [33]. People with a moderate or severe extent 
of WM hyperintensity were more likely to have experienced a lacunar stroke than those with mild 
WM hyperintensities [35]. On the other hand, large subcortical strokes such as striatocapsular 
stroke are less prevalent in people with WM hyperintensity of a moderate or severe extent 
compared to mild extent [36]. 
1.3.5 WM Disease Relationship with Cognition in Subcortical Stroke 
There is an established relationship between WM disease and cognition in people with subcortical 
stroke. In people with lacunar stroke, there is an increasing relationship between executive 
dysfunction and extent of WM hyperintensities [37].  Moreover, another study found that after a 
silent lacunar infarct, the reductions in FA in the left external capsule correlated to decreases in 
memory and language ability [38]. As for large subcortical stroke, a study showed that after 3 
months post-stroke, people with a stroke that had a poorer cognitive outcome had reduced FA in 
several WM regions on the contralateral side, while those with a good cognitive outcome only had 
reduced FA in the contralateral corpus callosum genu [39]. Overall, this suggests that an increasing 




1.4 Alzheimer’s Disease (AD) 
1.4.1 AD Stages and Diagnosis 
AD is a neurodegenerative disease, distinct from subtle cognitive loss associated with aging, 
characterized by progressive memory loss and the proteopathies of beta-amyloid (Aβ) and tau. 
Although the focus of this thesis is WM microglial activation, it is important to discuss the clinical 
pathogenesis of AD to contextualize our transgenic prodromal AD rat model. In terms of 
pathogenesis, Aβ deposits and plaques originate from amyloid precursor protein (APP), which is 
cleaved into Aβ monomers that eventually aggregate into deposits and [40]. As for tau, the 
microtubule-associated protein tau (MAPT) gene produces six splicing isoforms that bind 
microtubules and may undergo hyperphosphorylation before aggregating into neurofibrillary 
tangles [41]. Overall, Aβ and tau are both important diagnostic hallmarks of AD, but Aβ 
pathogenesis appears to start before tau pathogenesis. These proteopathies often precede the onset 
of memory loss, mild cognitive impairment, and mild AD, moderate AD, and severe AD [42,43]. 
Mild cognitive impairment precedes the progressive loss of memory known as dementia, which is 
diagnosed based on substantial concern and longitudinal decline in two cognitive domains 
including memory according to a mental status exam or neuropsychological testing such as the 
widely used clinical dementia rating. In addition to Aβ and tau proteopathies, clinical evidence 
also suggests that WM changes can occur early before cognitive impairment [44]. 
Although the above stages define the severity of AD, the clinical diagnosis of AD depends on the 
quality of evidence, which in increasing order can be classified as: possible AD, probable AD, and 
proven AD (Fig. 1.1) [45]. To give a diagnosis of proven AD, an antemortem diagnosis of possible 
AD or probable AD needs to be supplemented by post-mortem histopathology showing Aβ neuritic 




and neurofibrillary tau tangles in the neocortex and hippocampus as staged by Braak [46]. A 
diagnosis of AD may also be supported by post-mortem detection of Aβ deposits as scored by Thal 
et al. [47]. Overall, knowing these differences in diagnosis may help explain why some clinical 
studies differ in their results about the various white matter pathologies. 
 
Fig 1.1 AD diagnosis. Diagnosing a stage of AD is based on severity of symptoms, while non-
research diagnosis of AD is based on evidence including an AD-like decline of memory (possible 
AD), absence of other diseases (probable AD), and the histological presence of amyloid and tau 
(proven AD) [45] 
1.4.2 WM Microglial Activation and Disease in AD 
Before discussing WM microglial activation in AD, it is important to recognize that 
neuroinflammation in AD is still a subject of research [48]. In AD, the initial thought was that 
neuroinflammation only occurs at the site of amyloid deposition. Evidence suggested that 
excessive accumulation of amyloid induced microglial activation for clearance, which if 
insufficient led to amyloid deposition and persistent neuroinflammation that had a neurotoxic role 
[49–52]. Although that explained why neurotoxic activated M1 microglia and A1 astrocytes could 
be found at the neocortex and hippocampus, in which amyloid is usually deposited, it did not 
sufficiently explain recent findings that activated M1 microglia can be found in the WM of people 




The presence of WM microglial activation changes is controversial in people with late-
onset AD, but early-onset AD seems to have elevated WM microglial activation. To differentiate 
between early-onset AD and severity of AD, it is important to first discuss Braak staging in detail: 
Braak staging is often used to define the severity of neurodegenerative diseases using intensity and 
location of tau pathology; a Braak stage I is often localized to the lower brain stem and the earliest 
locations where pathology develops while a Braak stage VI has intense tau staining in those early 
locations and additionally has pathology in other locations including the neocortex [56]. Early-
onset AD with severe tau pathology indicated by a Braak stage V-VI has been shown to have 
elevated WM microglial activation in the transentorhinal cortex and frontal cortex, which 
according to Braak stages are some of the earliest and latest regions affected in AD respectively 
[4]. people with early-onset AD and early Braak stages were not investigated, this suggests that 
WM microglial activation may play a role at least during the late Braak stages of AD pathology. 
As for people with late-onset AD, histology studies have shown that WM microglial activation is 
similar between people with late-onset AD and controls [4].  
On the other hand, TSPO-PET data of people has been controversial; Kreisl et al. showed 
normal WM microglial or astrocyte activation in mild cognitive impairment and AD while 
Suridjan et al. showed elevated WM microglial activation in AD [57,58]. As only Suridjan et al. 
noted the presence of WM hyperintensities and both studies controlled for TSPO genotype and 
used structurally similar PET radiotracers, we speculate that an elevated WM microglial or 
astrocyte activation may be attributed to the presence of lesions or to a late stage of AD [49]. More 
research is needed to determine the stage at which WM microglial activation appears in humans. 
Rodent histological studies by our group have implicated WM microglial activation as an 




AD, which overexpresses human Swedish- and Indiana-mutated amyloid precursor protein 
(TgAPP21) to produce high levels of Aβ without depositing amyloid plaques, has elevated WM 
microglial activation that is proportional with age, correlates with executive dysfunction, and is 
predictive of eventual memory loss [53–55]. Accordingly, WM microglial activation may be 
related to other disease findings in WM of people with disintegration, demyelination, WM 
hyperintensities, and atrophy [59–61]. 
WM integrity as measured by DTI MRI is decreased in people with late AD, but the stage 
at which disintegration begins remains controversial. By late AD, most evidence supports that WM 
integrity has deteriorated [62]. In contrast, the evidence for earlier stages is conflicted. For 
example, a 1-year longitudinal and cross-sectional study by Nowrangi et al. showed that the most 
commonly used DTI measurement FA was and remained similar between healthy controls and 
people with mild cognitive impairment. There was an observed increase in the other DTI 
measurement of mean diffusivity, which the authors attributed to loss of neurons, axons, and 
dendrites, in people with mild cognitive impairment [61]. On the other hand, a study with a 2-year 
follow up by Zhuang et al. found that FA was initially lower in 16 people who were normal 
converted to amnestic cognitive impairment compared to 173 people who remained cognitively 
normal [44]. To resolve this conflict, a longitudinal study with a larger sample size is necessary 
and is expected to be provided by the Alzheimer's Disease Neuroimaging Initiative [63]. 
WM demyelination has also been detected throughout the course of AD using the myelin-
sensitive MRI measurement, magnetization transfer ratio (MTR). Magnetization transfer imaging 
can use the transfer of magnetization between protons of free water and those bound to 
macromolecules to measure MTR, which corresponds to myelin in WM. In one study, reduced 




but this was not detectable using mean MTR [64]. The limited reduction in MTR might imply that 
mild cognitive impairment represents an AD stage at which WM demyelination has not fully 
occurred.  In late AD, the loss of myelin has been histologically confirmed using Luxol fast blue 
staining [65].  
1.5 Measuring WM Microglial Activation 
Given the importance of WM in neuronal communication and the observation that microglial 
activation can have deleterious effects, it is important to study microglial activation in the WM. 
Amongst the many molecules that can mark microglial activation, our interests are in the major 
histocompatibility complex (MHC) class II molecules and translocator protein (TSPO). 
1.5.1 Major Histocompatibility Complex Class II (MHCII) Molecules 
MHCII molecules are important in adaptive immunity and often measured to study WM microglial 
activation in multiple sclerosis and AD. MHCII molecules are a group of molecules that are 
expressed by the MHCII region of the genome in organisms that have them, and include those that 
have a structure made up of an alpha chain and beta chain folding together to integrate in lipid 
membranes and make an extracellular domain for presenting antigens to other cells. A well studied 
example of this is the presentation of antigens to the T-cell receptor on CD4+ T cells, which is a 
type of adaptive immunity that could also have cytotoxic effects when activated [66]. In people 
with early-onset AD, a recent study has also demonstrated with immunohistochemistry (IHC) that 
microglial activation and MHCII molecules are increased in the WM [4]. Given observations of 
activated MHCII microglia in the WM of early-onset AD and the potential cytotoxic effects of 




1.5.2 Translocator Protein (TSPO) 
As mentioned in earlier sections, TSPO-PET has been used to observe chronic WM inflammation 
in people with subcortical stroke and people with AD [1,58]. This makes it an ideal candidate for 
in vivo imaging of chronic WM MHCII microglial activation. 
TSPO was discovered as a variant of the central benzodiazepine receptor that had 
differences in ligand binding and was expressed in the kidney, which led to its initial name 
peripheral benzodiazepine receptor (PBR) [67]. PBR was renamed to TSPO because of its 
implication in the intracellular movement of cholesterol, but some authors have stated that this 
lacks sufficient experimental proof [68,69]. Nevertheless, TSPO has been implicated in a variety 
of functions and as a marker of neuroinflammation [70].  
Neuroinflammatory expression of TSPO has been mostly attributed to activated microglia 
and, in some studies, activated astrocytes. Initial studies of rat brains reported that TSPO 
expression could be attributed to activated microglia and astrocytes [71,72]. Recent studies have 
suggested that TSPO is not expressed by astrocytes [73,74]. Astrocyte expression of TSPO may 
be circumstantial as stroke studies of TSPO have shown that the number of astrocytes expressing 
TSPO increases with time after a stroke [28,75,76]. 
1.6 Positron Emission Tomography (PET) 
Although MRI can quantify WM integrity, demyelination, hyperintensities, and the core and 
penumbra of a stroke, it cannot specifically measure microglial activation. WM microglial 
activation can, however, be measured in living subjects using TSPO-PET. In this thesis, the main 
objective was to determine whether TSPO-PET can detect WM microglial activation that is 




PET radiotracer production typically begins with a cyclotron that accelerates a positively 
charged particle into a target to produce positron-emitting radioisotopes. Positron-emitting 
radioisotopes such as 18F and 11C, which have a half-life of 109.7 and 20.4 mins respectively, are 
incorporated into exogenous agents with high affinity and specificity for the targeted molecule. 
When in the subject, the radiolabeled molecules accumulate at the regions of interest and emit high 
energy positrons that annihilate with nearby electrons to produce two antiparallel photons at an 
energy of 511 keV. These gamma rays exit the body to the PET scanner, where they are detected 
in coincidence and converted into a signal by a ring of scintillator arrays that is optically coupled 
to photodetectors. 
The acquired signal is stored in list-mode data set (containing detector locations and 
detection time for each coincidence event), processed into sinograms, and reconstructed into 
volumes portraying the distribution of PET tracer averaged over a period of time in a single frame 
or multiple frames. For a 3D acquisition, each frame of data can be binned into a set of N2 oblique 
sinograms between detector rings, where N is the number of detector rings and a sinogram is a 
graph that plots the number of coincidences detected for each possible detector pair [77]. 
Sinograms are corrected for random and scatter emission events before PET images are 
reconstructed using a filtered back projection reconstruction or iteratively by comparing them to 
the sinograms of different theoretical volumes. For example, the iterative reconstruction algorithm 
used in chapter 2, 3D ordered-subset expectation maximization followed by fast maximum a 
posteriori (OSEM3D/FMAP), works by dividing the measured sinograms into non-overlapping 
subsets and using only one subset at a time to minimize the difference between the measured subset 
and a theoretical subset that is based on the forward projection of a model image (OSEM3D), and 




1.6.1 PET Spatial Resolution 
As producing a PET volume requires information about detector location, detector size is inversely 
related to resolution, but it is also directly related to sensitivity. In other words, decreasing detector 
sizes could increase resolution by providing a better estimate of where gamma rays strike the PET 
instrument, but sensitivity would decrease as the detectors might become too small to detect a 
sufficient number of photons.   
System resolution is also limited by positron physics. For one, before annihilating with 
electrons to produce two 511 keV gamma rays, positrons can diffuse for a distance related to their 
maximum emission energy. The uncertainty about where the positrons were emitted poses a 
resolution limit. Second, resolution is limited because the produced gamma rays are not perfectly 
anti-parallel if the positron has residual momentum, which results in an angle that ranges from 
179.75° and 180.25°, which means that there is a range for where the annihilation could have 
happened. To reduce the range, the diameter of the bore could be decreased, but this is only feasible 
up to a limit. Overall, the resolution of any PET system is physically limited by the distance a 
positron could diffuse before annihilating and the fact that the produced gamma rays are not always 
perfectly anti-parallel. 
1.6.2 Radiotracer Target, Sensitivity, and Specificity 
Radiotracers may be divided based on their target reaction and kinetic behavior. Target reactions 
guide the initial process of radiotracer development; for the development of radiotracer to be 
worthwhile, it has to have clinically meaningful implications. Example reactions include 
physiological processes such as perfusion or blood-tissue exchange, but the majority of PET 
tracers developed target a protein [80]. Based on their kinetic behavior, radiotracers may be further 




achieve equilibrium by the end of an experiment while irreversible radiotracers generally do not 
achieve equilibrium. An example of an irreversible radiotracer is [11C]deprenyl, which binds by 
making a covalent bond with its target protein monoamine-oxidase B to estimate CNS amine 
breakdown such as that of dopamine [82]. Although an irreversible radiotracer is generally thought 
to be advantageous because it simplifies analysis, it can be disadvantageous by having limited 
sensitivity in regions of high target concentrations when there are insufficient amounts of 
radiotracer to saturate the targets [82].  
Sensitivity of PET radiotracers refers to their affinity to the target reaction, such as binding 
for neuroreceptor radiotracers and delivery for flow radiotracers, and can be validated in vitro, ex 
vivo, and in vivo. Affinity to the target reaction is a practical concept for quantifying how 
effectively the radiotracer could detect the target reaction. For reversibly binding tracers, in vitro 
samples containing the target are usually subject to competitive binding assays as part of the initial 
validation of a radiotracer [83]. Later studies may validate in vivo binding affinity by injecting a 
cold competitive binder in experiments of blocking or displacement, but this is not feasible for all 
target reactions. For example, blocking or displacement studies are not feasible for TSPO because 
an unsafe concentration of cold binding molecules is required to saturate the many TSPO binding 
sites in the body [84].  
PET radiotracer specificity is one of the most prevalent reasons for why radiotracers fail, 
and although there are in vitro approaches to quantify specificity, they do not always correspond 
to in vivo results. Radiotracers often fail in vivo because they bind to off-target proteins or lipids, 
which could have misleading consequences. Ideally, in vitro tests would have been conducted to 
evaluate radiotracer specificity. For brain studies, a high lipophilicity of the radiotracer often 




lipophilicity and still demonstrate nonspecific binding in vivo; in these cases, competitive binding 
experiments that can quantify sensitivity show a high PET signal after injection of the competitive 
molecule.  
1.6.3 Tracer Kinetic Modelling 
Tracer kinetic modelling has the practical purpose of condensing dynamic information into 
quantities of the primary processes that affect tracer distribution. PET experiments can produce a 
lot of dynamic information because, after being injected into a subject, tracers do not 
instantaneously get distributed according to the quantity of the target reaction. Instead, the tracer 
dynamically experiences two or more processes including delivery, clearance, and the target 
reaction. As a result, the tracer undergoes dynamic change, and this can be seen by plotting the 
tracer radioactivity against time to construct what is frequently referred to as a time-activity-curve. 
Although for an ideal radiotracer, an estimate of the target reaction may be semi-quantified using 
a single late timepoint activity measurement such as standardized uptake value (SUV) normalized 
to the injected dose and subject weight or the later-discussed reference region-based uptake ratio 
(UR - often called SUVR), it is possible to use tracer kinetic modelling to obtain an exact rate 
measurement of the target reaction, delivery, clearance and other reactions or processes. By 
condensing a lot of information into exact rate measurements, tracer kinetic modelling serves a 
practical purpose. 
The types of rates and their interpretation depend on the chosen tracer kinetic model. 
Although more complicated models can be more informative, they are computationally demanding 




1.6.3.1 Compartmental Modelling 
Compartmental models are well-suited to maximize the current abilities of PET. Compartmental 
tracer kinetic models are based on how the rate of reactions are linearly related to their rate constant 
and substrate concentration, which may be considered uniform using conceptual compartments 
such as states, locations, or their combination. In reality, there are many theoretical tracer 
compartments, but the ability to resolve them are limited by current insufficiencies in PET 
including signal, resolution, and the inability to distinguish radioactivity sources [85]. Instead, 
these PET insufficiencies and the ability to make uniformity assumptions dictate whether a 
compartment is resolvable. In doing so, compartmental models maximize the number of practical 
parameters that can be accurately extracted from PET data. 
The 2TCM provides the highest number of parameters that are usually solved for in PET 
studies. It is based on the distinction of two tissue compartments: a nondisplaceable compartment 
(C1) that is in equilibrium with the bound compartment (C2), with a tracer-dependent distinction 
between a plasma compartment (Cp) and a blood compartment (Cb). Having been designed for 
tracers with slow reversible reactions, the 2TCM has 5 microparameters: K1 = plasma-to-
nondisplaceable-compartment transfer rate (delivery), k2 = nondisplaceable-compartment-to-
plasma transfer rate (clearance), k3 = nondisplaceable-compartment-to-target-compartment 
transfer rate, k4 = target-compartment-to-nondisplaceable-compartment transfer rate, and Vb = 
blood volume fraction (Fig. 1.2) [86]. Each of these parameters has an important clinical relevance. 
Namely, K1 equates to the product of blood flow and tracer extraction fraction, the latter of which 
is related to permeability of the BBB in PET studies of the brain. Both of these measurements 
could be affected by a pathology. On the other hand, k2 is related to K1; if blood flow changes K1, 




change the blood-volume fraction. Lastly, k3 and k4 correspond to the in vivo- and tracer-dependent 
rate estimates of association with the available target protein and its reversal, respectively. As these 
two rate estimates are related to the amount of the target molecule, which should have a clinically 
significant interpretation, the 2TCM is usually used when possible.  
An important requirement of the 2TCM is that it requires invasive blood sampling and 
metabolite fractionation to determine the fraction of non-metabolized radiotracer in the plasma 
(Cp) and the blood compartment (Cb). This is because radiotracers can be metabolized and the 
metabolites cannot be differentiated from the parent by the PET detector. To model only the parent, 
its fraction in the arterial blood is required. Given the invasive nature of arterial sampling, non-
invasive methods to derive the input function are actively being pursued [89,90].  
 
Fig 1.2 A visual representation of a 2TCM. In this model, the plasma pool (Cp) is distinguished 
from the whole blood pool (Cb). When the whole blood pool is multiplied by the volume fraction 
of tissue that is occupied by blood vessels (Vb), the blood-sourced activity (Vb x Cb) can be 
separated from the rest of the tissue (C1 and C2), which all together makes up the detector-measured 
CT as defined in Eq 1.3. The radiotracer gets exchanged and eventually achieves equilibrium 
between Cp and C1, and between C1 and C2. The rates at which the parent radiotracer is exchanged 
between compartments are indicated using K1 (delivery), k2 (clearance), k3 (binding), and k4 
(unbinding) 
Compartmental models are often solved using the nonlinear least-squares approach, but 
this can produce inaccurate microparameters [91,92]. The approach continually alters parameters 




and, usually, derivative-based algorithms. Unfortunately, derivative-based algorithms require an 
accurate initial estimate to converge to the global optimum as there can be more than one local 
optimum, which is the result of noise and inversely correlated model parameters [91,93]. As 
nonlinear least-squares algorithms are more likely to find the global optimum if the parameter 
search space is smaller, most studies eliminate one dimension by fixing Vb to a predetermined 
value. Another way to reduce the number of dimensions can be used for the 2TCM; blocking or 
displacement experiments may be used to simulate a scenario where are k3 and k4 equal to zero, 
but as mentioned earlier, these are not feasible for all PET targets. On the other hand, the 
parameters may also be reduced by setting k3 and k4 to zero, which is valid if the tracer kinetics 
may effectively be modeled with a single tissue compartment model (1TCM) when the tracer does 
not have a target reaction beyond delivery or if the target reaction rapidly achieves equilibrium 
[94]. Overall, the inability to estimate the initial target parameters and the local minimum problem 
make it challenging for the nonlinear least-squares-fitting approach to prove that the converged 
parameters are the true parameters [95].  
1.6.3.2 Total Distribution Volume (VT) 
Regardless of method, most PET papers that use tracer kinetic modelling on reversible binding 
ligands report the robust but aggregated macroparameter VT. VT is defined as the equilibrium ratio 
of radiotracer concentration in the region of interest, not including the blood component, to that in 
plasma (Eqs. 1.1 and 1.2). A downside to this definition is that VT largely consists of the 
equilibrium concentration in the non-displaceable compartment, making VT an aggregated 
macroparameter that is not purely representative of the target binding reaction. On the other hand, 
this activity-ratio-based definition allows for robust calculation of VT; VT will be accurate if the 




(equations below). Overall, despite VT being an aggregated macroparameter that contains 
information about the non-displaceable compartment, its activity-ratio definition makes it a robust 
parameter to report. 




Eq 1.2 (2TCM):   𝑉𝑇 =
𝐾1
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1.5.3.3 Logan Graphical Analysis 
Logan graphical analysis is one of the most widely used methods for determining VT of reversibly 
binding tracers. It started in 1990, when Patlak’s work on graphical analysis of non-reversible 
tracers inspired Logan to extend the work to reversible tracers [96]. At the time, Logan graphical 
analysis provided a method to solve VT that was computationally simple, robust, and does not 
require the specification of a compartmental model; although based on compartment models, 
differentiating between them does not change the slope on the graphical analysis and therefore 
distribution volume. Improvements in PET signal-to-noise ratio have increased the robustness of 
Logan graphical analysis by correcting earlier underestimates of VT [97]. Given this improvement 
in signal-to-noise ratio, the simplicity, and model-independence of Logan graphical analysis, it is 
no surprise that Logan graphical analysis is still one of the most widely used methods for 
calculating VT. 
Logan graphical analysis follows the simple linear regression equation Y = slope•X + 
intercept. Although Logan analysis is model-independent, the interpretation of the slope and 
intercept depends on the model and assumptions. For a 2TCM that distinguishes between the 




plasma, a full solution is provided in Appendix A. Briefly, the model, assumptions, and solution 
are as follows: 
Eq 1.3:             𝐶𝑇(𝑡) = 𝐶1(𝑡) + 𝐶2(𝑡) + 𝑉𝑏𝐶 𝐵(𝑡)              
Eq 1.4:             
𝑑𝐶1(𝑡)
𝑑𝑡
=  𝐾1𝐶𝑝(𝑡) −  𝑘2𝐶1(𝑡) −  𝑘3𝐶1(𝑡) +  𝑘4𝐶2(𝑡)  
Eq 1.5:                 
𝑑𝐶2(𝑡)
𝑑𝑡
=  𝑘3𝐶1(𝑡) − 𝑘4𝐶2(𝑡)  
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𝐶𝑇 = Concentration of total radioactivity in the tissue 
𝐶𝑝 = Concentration of free parent metabolite in the plasma 
𝐶𝐵 = Concentration of total radioactivity in whole blood 
𝐶1 = Concentration of parent metabolite in the non-displaceable compartment 
𝐶2 = Concentration of parent metabolite in the bound compartment 
𝑉𝑏 = The ROI volume fraction of vascular tissue 
𝐾1 = plasma-to-unbound-compartment transfer rate (delivery) 
𝑘2 = unbound-compartment-to-plasma transfer rate (clearance) 
𝑘3 = unbound-compartment-to-bound-compartment transfer rate (binding) 




1.6.4 Reference Regions 
In PET studies, reference regions techniques make quantification convenient because they omit 
the need for invasive blood sampling and microparameter fitting. Blood sampling can be avoided 
when using reference regions techniques because they omit the need for concentration of free 
parent metabolite in the plasma, the obtaining of which (i) is invasive because it requires 
catheterization for blood samples and (ii) labor-intensive and error-prone because it requires 
methods for extracting metabolite fractions from blood samples. An example of such a technique 
is the semi-quantitative uptake ratio approach (UR), which relies on the assumption that there are 
no unmetabolized radioligands in the reference region. Additionally, to determine the important 
ratio of radiotracer concentration in the specifically bound compartment to that in the 
nondisplaceable compartment (BPND), error-prone microparameter fitting can be avoided by using 
reference regions and the Logan VT-based reference region techniques (equation below). This 
requires the assumption that the reference region is physiologically identical to the region of 
interest except for the target reaction(s) being quantified, which in the reference region should be 
nonexistent. Therefore, given the right assumptions, reference region techniques are convenient 
because they allow the determination of BPND without error-prone microparameter fitting and, also 
for determining the semi-quantitative UR, without blood sampling and metabolite analysis. 













Where Vs is the distribution volume in the bound compartment and VND is the distribution 




1.6.5 Ex Vivo PET Validation 
Quantitative validations of PET are usually done using the ex vivo methods of autoradiography 
and western blotting. Relative to PET, autoradiography allows validation of the PET radiotracer 
at a higher resolution and, importantly, simpler binding context. The higher resolution is derived 
by placing tissue sections incubated with radiotracer closer to high-resolution detectors than 
possible with PET. Analysis of binding is simplified because (i) the radiotracer does not need to 
pass a blood compartment, (ii) equilibrium can be achieved rapidly, and (iii) the non-specific 
binding can be assessed using non-radioactive ligands at toxic concentrations [98]. In contrast, 
western blotting resolution is technically limited, but it can produce pure quantitative 
measurements of the target protein amount. The user must sample a region of interest, homogenize 
it, separate it in a gel, incubate it with a target-protein-binding chromogenic antibody complex, 
then use the amount of signal it emits to quantify protein amount by regression from predetermined 
quantities of standard proteins [99]. Overall, autoradiography provides high resolution of 
radiotracer binding while western blotting provides accurate quantities of the target protein without 
the need to quantify binding constants.  
1.6.5.1 Immunohistochemistry (IHC) 
IHC provides a very high resolution of the target protein, but the measurements are semi-
quantitative. Briefly, IHC is when tissue sections are incubated with a chromogenic antibody 
complex that can be imaged with high-resolution microscopes. IHC resolution is much higher than 
PET because (i) the chromogen is near the target protein and (ii) the physical laws that limit 
microscopy are much less restrictive. Unfortunately, traditional IHC is semi-quantitative and 
restricted to counting or area coverage analysis because the protein-to-signal relationship is not 




is not stoichiometric but can also be attributed to chromogens that do not follow Beer-Lambert’s 
law. All together, although IHC is semi-quantitative, the process and physical laws give it a much 
higher resolution than PET.  
1.6.6 TSPO-PET 
Given the ability of TSPO to mark activated microglia that was mentioned in section 1.5.2, and 
the knowledge of ligands that can bind TSPO, many TSPO-targeting radiotracers have been 
developed to quantify microglial activation in vivo [100]. Initial radiotracers included those based 
on benzodiazepines such as [11C]Ro5-4864 and isoquinoline carboxamides such as [11C]PK11195. 
In a later generation, [11C]Ro5-4864 binding inspired the development of [11C]DAA1106 and other 
phenoxy acetamides with high binding affinity such as [11C]PBR28 and [18F]FEPPA. New 
radiotracers for TSPO continue to be developed because of quantification issues. 
TSPO-PET quantification has been hindered by low binding specificity in the initial 
radiotracer [11C]PK11195, sensitivity to human polymorphisms in newer generation tracers, and 
the absence of a true reference region. The first PET tracer was [11C]PK11195, but its low binding 
specificity limited the signal-to-noise ratio of true TSPO expression [101]. Binding specificity was 
improved in newer generation PET tracers, but they proved sensitive to TSPO human 
polymorphisms and therefore additionally required a genetic analysis for accurate quantification 
[102]. This polymorphism sensitivity initially seemed solved by [18F]GE180 and the yet newer 
radiotracer [11C]ER176, but these were later revealed to be artifacts or did not translate from in 
vitro studies to in vivo studies respectively [103,104]. Finally, the absence of a true reference 
region that is devoid of TSPO expression has made it technically challenging to quantify PET 




1.7 Rationale and Objectives 
AD and subcortical stroke are both common neurological diseases with unfortunate cognitive 
prognoses. Although their main pathologies are different, WM microglial activation and other WM 
abnormalities are key components to the pathogenesis of both AD and stroke. Specifically, our 
group has used preclinical co-morbid rodent models of disease to demonstrate that diffuse WM 
microglial activation increases with normal age, is accelerated in transgenic AD rats and following 
subcortical stroke, associates with executive dysfunction, and is predictive of learning and memory 
impairment [29,30,53,55,106]. 
To longitudinally measure cognitive function and WM microglial activation , there is a need 
for an in vivo imaging modality that can image WM microglial activation. As TSPO-PET can 
quantify microglial activation and has been used to observe chronic WM inflammation in 
subcortical stroke and AD, we hypothesized that the chronic WM microglial activation that is 
histochemically detected using MHCII in our subcortical stroke and prodromal AD rat models can 
also be detected using TSPO-PET. To test this hypothesis, this thesis had the following objectives: 
1. To investigate WM microglial activation in a rat model of prodromal AD with TSPO-PET 
using the 2nd generation radiotracer, [18F]FEPPA. 
2. To investigate WM microglial activation longitudinally in a rat model of subcortical stroke 
with TSPO-PET. 
3. To investigate and validate WM TSPO expression in a rat model of subcortical stroke at 7-
days and 28-days using IHC. 
4. To investigate WM microglial and astrocyte activation in a rat model of subcortical stroke 
using MHCII, iNOS, and GFAP IHC at 7-days and 28-days post-stroke. 




Results from these studies are reported in Chapter 2, which is currently under review for 
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Chapter 2: TSPO PET Detects Acute Neuroinflammation but not Diffuse Chronically Activated 
MHCII Microglia in the Rat 
The figure numbers were modified to fit in this thesis. Additional changes were made to this 
manuscript since being submitted for publication. 
2.1 Introduction 
Diffuse inflammation of brain white matter (WM) has been clinically implicated in the pathology 
of brain diseases including schizophrenia, traumatic brain injury, and Alzheimer’s Disease [1–3]. 
In the continuum from mild cognitive impairment to Alzheimer’s disease (AD), diffuse WM 
inflammation may explain why WM undergoes demyelination, tract disintegration, and atrophy 
while patients undergo cognitive decline [4–6]. To measure WM inflammation in living subjects, 
previous studies have used PET tracers that target the 18 kDa translocator protein (TSPO) [7,8]. 
TSPO is overexpressed in astrocytes and microglia during their activation, but the subtypes of 
activated microglia that express TSPO remains a subject of research. 
Microglia that express major histocompatibility complex class II (MHCII) molecules, 
which are involved in antigen presentation, are considered to be proinflammatory [9]. MHCII 
molecules are correlated to cognitive dysfunction throughout AD and diffusely overexpressed in 
the WM microglia of patients with early-onset AD [1,10]. Previously, our group correlated diffuse 
MHCII activated microglia in WM with cognitive dysfunction in a prodromal transgenic rat model 
of AD that overexpresses human Swedish- and Indiana-mutated amyloid precursor protein 
(TgAPP21) to produce high levels of Aβ without depositing amyloid plaques [11–13]. We further 
demonstrated the importance of diffuse MHCII activated microglia by detecting them in WM 




executive dysfunction [14,15]. Overall, these observations motivate the need to detect MHCII 
activated microglia in vivo. 
In this study, we used the TgAPP21 and ET1-induced subcortical stroke rat models to 
investigate whether TSPO can detect diffuse MHCII activated microglia in WM. To quantify 
TSPO in vivo, we used a second-generation TSPO PET tracer ([18F]FEPPA) and validated the 
cerebellum as a pseudoreference region [16]. TSPO-PET was validated using 
immunohistochemistry of TSPO, which was compared to the activated astrocyte marker GFAP 
and activated microglia markers iNOS and OX6 (MHCII) in ET1 rats.  
2.2 Methods 
2.2.1 Animals and Experimental Design 
Animal ethics and procedures of this study are in compliance with the Canadian Council for 
Animal Care and Western University Animal Care Committee (Protocol 2014-016). Rats were 
housed under a 12h/12h light/dark cycle and received access to food and water ad libitum. 
This study used male Fischer 344 rats aged 11-14 months. TgAPP21 (n = 11) and wild-
type (n = 12) rats were randomly selected to investigate [18F]FEPPA uptake in WM of prodromal 
AD. Genotype was validated with PCR as previously described [13].  
To study ischemic subcortical stroke, the same wild-type rats that received baseline in vivo 
imaging were randomly assigned to a stereotactic injection of 60 pmol endothelin-1 (ET1) 
dissolved in 3 μL sterile saline (n = 5) or sterile saline alone for control (n = 6) in the right dorsal 
striatum as previously described [17]. Rats were imaged in vivo post-stroke at day 7 and day 28, 
at which point they were euthanized for immunohistochemistry. A saline rat was omitted at day 7 




An additional group of rats (n = 5 ET1, n = 6 saline) was euthanized at day 7 for acute 
immunohistochemistry.  
2.2.2 In Vivo Imaging 
Each in vivo imaging session consisted of a PET scan followed by MRI and CT. Before PET, 
anesthesia was administered at 2 L/min oxygen with 5% isoflurane for induction then maintained 
at 2% until after CT. Respiratory rate, heart rate, and body temperature were monitored and 
maintained throughout. 
2.2.2.1 MRI 
MRI was performed on a 3T MRI (Siemens Biograph mMR) with a dedicated quadrature rat brain 
coil (Cubresa, 44 mm inner diameter). 2D sagittal and axial T2-weighted fast spin echo (FSE) 
images were acquired spanning the brain with an in-plane field-of-view (FOV) = (70 x 70) mm2, 
matrix size = 320 x 320, in-plane resolution = (0.22 x 0.22) mm2 and slice thickness = 1 mm. Other 
relevant parameters for the FSE sequence include: repetition time (TR) = 2930 ms (sagittal 
acquisition) and 3900 ms (axial acquisition), effective echo time = 97 ms, refocusing flip angle = 
150°, echo train length = 11, bandwidth = 225 Hz/pixel, and averages = 4. 
2.2.2.2 CT 
For attenuation correction of the PET, full-body helical CT scans were acquired with a resolution 
of (0.20 x 0.20 x 1.25) mm3, tube current = 80 mA, tube voltage = 80 kVp, and rotation time = 1 
s (GE Revolution CT). CT images were segmented using Hounsfield-unit thresholds into tissue 




2.2.2.3 PET Acquisition and Processing 
PET data was acquired dynamically over 90 minutes (Siemens Inveon). Thirty seconds after 
initiating the scan, 33.7 ± 5.6 MBq [18F]FEPPA was injected through a tail vein catheter. On day 
28, rat tail arteries were cannulated for blood sampling (n = 4). A blood volume of 50 µL was 
sampled into tubes with ethylenediaminetetraacetic acid at 2, 8, 16, 64, and 90 minutes post-
injection. Blood was centrifuged to extract 15 uL of plasma, which was then loaded onto 
omniphilic cartridges (Oasis HLB, Waters). Fractions were eluted with 0%, 20%, and 40% 
acetonitrile in 1 mL of solution to elute successively more lipophilic metabolites [18]. Elutants, 
blood, and plasma were counted using a calibrated gamma detector. 
Decay-corrected PET data from 70-90 minutes post-injection was used for standardized 
uptake value (SUV) analysis and dynamic frames of 1 x 27 s, 21 x 3 s, 12 x 10 s, 5 x 30 s, 4 x 60 
s, and 16 x 300 s for pharmacokinetic modeling. Appendix B contains time-activity curve 
examples of the initial phase and full phase for the input function and critical regions as outlined 
in Fig. 2.1: infarct region, contralateral to the infarct region, ipsilateral corpus callosum, and 
contralateral corpus callosum. PET reconstruction consisted of 2 iterations of 3D ordered-subset 
expectation maximization followed by 18 iterations of fast maximum a posteriori 
(OSEM3D/FMAP) with a co-registered CT-based attenuation correction map. 
2.2.2.4 PET Analysis 
Co-registration, region of interest (ROI) segmentation, and data extraction were performed using 
3D Slicer 4.10 [19]. Images were zero-interpolated to an isotropic 0.22 mm voxel size and linearly 
co-registered to define the ROI in each rat (Fig. 2.1). ROIs included the T2w-hyperintense infarct 
region and contralateral to the infarct region for a positive control, periaqueductal gray, 




callosum remote to the infarct. A 4 mm3 spherical ROI was placed in the centre of the cardiac left 
ventricular cavity to derive input functions. Input functions were corrected using biexponential 
and Hill function population fits of whole blood-to-plasma ratio and unmetabolized [18F]FEPPA-
to-all metabolites  ratio  (MATLAB 2019a).  Corrected input functions and time-activity curves 
were used with an assumed blood volume of 5% to solve for the Logan total distribution volume 
(DV – also known as VT) and ratio (DVR) using custom MATLAB scripts. Standardized uptake 
value (SUV) was calculated based on weight and injected dose then used to calculate uptake ratios 






Fig 2.1 Analytical Methods. a Representative ROIs delineated on T2w MRI and applied to fused 
[18F]FEPPA PET in a control rat at day 7. ROIs are proximal to the rat nose. b Infarct at baseline 
and post-stroke day 7 and 28 on T2w MRI. c, contralateral; CC, corpus callosum; CIR, contralateral 
to the infarct region, FM: Forceps Minor; i, ipsilateral; IR, infarct region; p, posterior 
2.2.3 Immunohistochemistry 
All rats were euthanized with an intraperitoneal injection of pentobarbital (Euthanyl, Bimeda MTC 
Animal Health Inc) then underwent transcardiac perfusion using 10 mM phosphate-buffered saline 
(PBS) followed by 4% paraformaldehyde (PFA). Brains were extracted, fixed in 4% PFA for 24h, 
then stored at 4°C in 30% sucrose until they were cryosectioned into 30 µm thick sections 




all tissue was available for 3,3′-Diaminobenzidine immunohistochemistry with avidin-biotin 
complex amplification (ABC Staining Kit, Thermo Fisher Scientific). Primary antibodies were 
anti-TSPO (1:1000, ab154878, abcam) for TSPO+ cells, anti-iNOS (1:1000, ab15323, abcam) for 
proinflammatory microglia, anti-OX6 (1:1000, #554926, BD Pharmingen) for MHCII, and anti-
GFAP (1:2000, #G3893, Sigma-Aldrich) for activated astrocytes. We used anti-OX6 because it 
targets the rat MHCII gamma chain, which is necessary for the proper function of all MHCII 
molecules. GFAP is often used as a marker of activated astrocytes because they need it for reactive 
astrogliosis and scar formation.  
The observer was blinded to experimental group during analysis. Images were acquired 
using a Nikon Eclipse Ni-E microscope and Nikon DS Qi2 colour camera on the NIS Elements 
Imaging software at a consistent lamp voltage and exposure for each antibody. TSPO cells were 
counted using four 20x sections at opposite borders of each defined in vivo region except the 
posterior corpus callosum, which used eight. Weak or diffuse staining was considered negative. 
GFAP, iNOS, and OX6 within-region % area coverage analysis used large images stitched from 
10x magnification fields. Regions were manually defined using the polygon tool to replicate in 
vivo delineations of the proximal corpus callosum and forceps minor. The infarct and contralateral 
regions were also defined for iNOS. Images were binarized with a consistent threshold to get % 
area coverage within each region (ImageJ 1.52a) [12]. 
2.2.4 Statistical Analysis 
All analyses of variance (ANOVA) were based on type III sum of squares (SPSS 26). To start, a 
two- or three-way ANOVA (depending on whether time was a variable) was conducted on PET 
(between ET1, within region and time) and immunohistochemistry (between ET1 and time, within 




effects with lower-order ANOVA and pooled variances if appropriate. Within-subject sphericities 
were accounted for using Greenhouse-Geisser corrections. Posthoc analyses for repeated timepoint 
effects were evaluated using Tukey’s honestly significant differences (HSD) unless Shapiro-Wilk 
normality or Levene’s variance assumptions were violated, in which case the Wilcoxon signed-
rank or Mann-Whittney U test were used, depending on whether samples were paired. Correlation 
and graphing were performed on GraphPad Prism 7. All data is expressed as mean ± standard 
deviation (SD). Significance was set at alpha = 0.05. 
2.3 Results 
2.3.1 The Cerebellum is an Appropriate Pseudoreference Region for [18F]FEPPA PET 
To determine an appropriate pseudoreference region for quantifying [18F]FEPPA uptake, 
[18F]FEPPA PET 70-90  min  SUVs  of  the  cerebellum  and  periaqueductal  gray were compared 
(Figs. 2.2 and 2.3). The region contralateral to the infarct was also compared in the ET1 
investigation. SUV was not significantly affected by genotype, ET1, or interaction between ET1 
and timepoints (P = ns for two-way and three-way ANOVA). Interestingly, region was a 
significant factor in both analyses of TgAPP21 vs. wild-type rats (A.U.: periaqueductal gray = 
0.43 ± 0.14; cerebellum = 0.56 ± 0.18; F(1,21) = 53.30, P < 0.0005, two-way ANOVA) and ET1 
vs. saline rats (A.U.: periaqueductal gray = 0.43 ± 0.12; region contralateral to the infarct = 0.49 
± 0.19; cerebellum = 0.60 ± 0.15; F(2,12) = 27.47, P = 0.001, three-way ANOVA). TSPO 
immunohistochemistry cell count of the day 28 infarct site also correlated better with the UR 
calculated using the cerebellum (R2 = 0.63, P = 0.0191) instead of the region contralateral to the 
infarct (R2 = 0.47, P = ns) or periaqueductal gray (R2 = 0.36, P = ns) (Fig. 2.5). Accordingly, 





Fig 2.2 SUV was significantly different between the pseudoreference regions, cerebellum and 
PAG, in wild-type and TgAPP21 [F(1,21)=53.30, P<.0005, two-way ANOVA]. Whole brain SUV 
is also shown. CIR: contralateral to the infarct region. PAG: periaqueductal gray. Error = SD 
 
 
Fig 2.3 Wild-type saline and ET1 rat pseudoreference regions at baseline, day 7, and day 28 after 
an injection in the right dorsal striatum. (A) SUV maps overlaid on T2-weighted MRI. (B) SUV 
showed a significant effect of region [F(1,21)=53.30, P<.0005, three-way ANOVA]. CIR, 






Fig 2.4 Correlations of distribution volume with distribution volume ratio to candidate 
pseudoreference regions. Each point represents one region in one Wt rat at the 28-day post-stroke 
timepoint. The coefficients of determination were derived within each rat, averaged, and are 
provided in the graph. CIR, contralateral to the infarct region; PAG, periaqueductal gray 
 
 
Fig 2.5 Correlations of infarct TSPO immunohistochemistry to uptake ratios calculated using 
candidate pseudoreference regions. Regression coefficients are provided in the graph. CIR, 
contralateral to the infarct region; PAG, periaqueductal gray; IR, Infarct region 
2.3.2 [18F]FEPPA UR was not Elevated in WM of TgAPP21 Rats 
UR in TgAPP21 and wild-type rats were analyzed to investigate [18F]FEPPA uptake in WM 
regions in which our group previously demonstrated MHCII microglial activation [12,13]. 
Genotype did not have a significant effect (P = ns, two-way ANOVA, Fig. 2.6). This suggested 
that [18F]FEPPA PET was not detecting the WM MHCII microglia that were previously reported 





Fig 2.6 Transgenic amyloid precursor protein rats did not have an elevated [18F]FEPPA PET WM 
uptake ratio, to the cerebellum, relative to wild-type saline rats. Genotype effect was not significant 
(P = ns, two-way ANOVA). CC, corpus callosum; FC, frontal cortex; FM, Forceps Minor; p, 
posterior. Error = SD 
2.3.3 [18F]FEPPA UR was not Elevated in Remote WM Following ET1-induced Stroke  
UR at baseline, day 7, and day 28 after injection of ET1 or saline were analyzed to investigate 
[18F]FEPPA uptake in WM with the infarct as a positive control (Fig. 2.7). An interaction between 
region, timepoint, and ET1 suggested that UR was increased following ET1-induced stroke only 
in regions near the infarct [F(20,120) = 3.66, P = 0.036, three-way ANOVA]. In the infarct ROI 
of the ET1 group, UR significantly increased from baseline (0.94 ± 0.16) to day 7 (2.10 ± 0.78; P 
= 0.043, Wilcoxon signed-rank) and day 28 (1.77 ± 0.35; P = 0.043, Wilcoxon signed-rank). 
Similarly, proximal WM (ipsilateral corpus callosum) UR of the ET1 group significantly increased 
from baseline (0.94 ± 0.12) to day 7 (1.42 ± 0.34; P < 0.005, Tukey’s HSD) and day 28 (1.38 ± 





Fig 2.7 [18F]FEPPA UR was not elevated in remote WM following ET1-induced stroke. a Maps 
and b values of longitudinal [18F]FEPPA PET uptake ratio, relative to the cerebellum, revealed a 
significant region-ET1-timepoint interaction in saline and ET1 rats [F(20,120) = 3.66, P = .036, 
three-way ANOVA]. c, contralateral; CC, corpus callosum; CIR, contralateral to the infarct region; 
FM, Forceps Minor; i, ipsilateral; IR. infarct region; p, posterior. Error = SD 
2.3.4 TSPO was not Expressed in Remote WM Following ET1-induced Stroke 
TSPO immunohistochemistry-based cell counting was performed to confirm [18F]FEPPA PET 
findings in stroke. An interaction between region and ET1 suggested that TSPO 
immunohistochemistry concurred with [18F]FEPPA on the finding that ET1 increased TSPO only 
in regions near the infarct ([F(9,117) = 27.04, P < 0.0005], three-way ANOVA, Fig. 2.8). In the 
infarct, ET1 significantly increased TSPO cell count at day 7 (cells/mm2: saline = 48± 43; ET1 = 
555 ± 181; P = 0.014, Mann Whitney U test) and day 28 (cells/mm2: saline = 6 ± 6; ET1 = 307 ± 
153; P = 0.025, Mann Whitney U test). Proximal WM (ipsilateral corpus callosum) TSPO cell 




disagreed by showing no day 28 elevation (5 ± 7 cells/mm2) (Fig. 2.9). Remote WM TSPO cell 
counts were low and unaffected by stroke (Figs 2.9 and 2.10). Recognizing that spillover of PET 
signal from the infarct into the ipsilateral corpus callosum might indicate an increased uptake in 
[18F]FEPPA PET when there is no TSPO overexpression, we used TSPO immunohistochemistry 







Fig 2.8 Immunohistochemistry showed that TSPO, but not iNOS, was elevated in the infarct site 
of ET1 rats at days 7 and 28 post-stroke. a Representative images of OX6 (MHCII), GFAP, iNOS, 
and TSPO in the infarct region (IR) and contralateral to the IR (CIR) post-stroke at day 7 and day 
28 in saline and ET1 rats. b Quantification of cell count for TSPO and % area coverage for iNOS. 







Fig 2.9 TSPO Immunohistochemistry of WM at day 7 and day 28 in saline and ET1 rats. (A) 
Representative images and (B) quantification of cell count for TSPO. FM, Forceps Minor; CC, 
corpus callosum; i, ipsilateral; c, contralateral; p, posterior. Bar indicates 100 µm. Error = SD 
2.3.5 GFAP and iNOS Expression was not Changed in WM Following ET1-induced Stroke 
GFAP and iNOS immunohistochemistry were performed to further investigate changes in 
astrocytes and microglia as these markers are often compared with TSPO [20,21]. GFAP signal 
showed a day 7 border around the infarct and a day 28 scar in ET1 rats, but there were no significant 
effects in WM (P = ns, three-way ANOVA, Fig. 2.10). iNOS signal showed sensitivity to ET1 
only in the infarct (% area: day 7 = 1.84 ± 2.16; day 28 = 4.74 ± 5.65; P = ns), without significance, 
and was not elevated in WM (P = ns, three-way ANOVA) (Figs. 2.8 and 2.10). Overall, GFAP 
and iNOS concurred with TSPO immunohistochemistry, with no significant changes in remote 





Fig 2.10 WM immunohistochemistry in the contralateral corpus callosum (CC c) showing that at 
28 days post-stroke, ET1 rats only showed an elevation of OX6 (MHCII); not TSPO, iNOS, and 
GFAP. a Representative images and b quantification of cell count for TSPO and % area coverage 
for other markers. Bar indicates 100 µm. Error = SD 
2.3.6 MHCII-Positive Activated Microglia were Chronically Expressed in Remote WM 
Following ET1-induced Stroke 
Immunohistochemistry of the MHCII rat antigen OX6 was used to confirm previous findings by 
our group of an ET1-induced increase of remote WM MHCII positive microglia activation (Fig. 
2.10) [14,15]. WM OX6 signal was significantly affected by an interaction between timepoint and 
ET1 [F(1,15) = 9.73, P = 0.007, three-way ANOVA]. Although there were no significant 
interactions with region, we separately analyzed the contralateral corpus callosum at day 28 and 
found a significant effect of ET1 (% area saline = 0.62 ± 0.38, ET1 = 4.30 ± 2.83; P = 0.029, Mann 
Whitney U test). This indicated that by day 28 post-stroke, MHCII was the only marker to show 





Literature about the non-specificity of TSPO to activated microglia is growing, but there are few 
reports showing that TSPO does not colocalize with all activated microglia or is not as sensitive 
as MHCII [22–24]. We found that [18F]FEPPA PET did not capture the expected increase of 
diffuse, chronically activated MHCII microglia in WM of TgAPP21 rats. Additionally, in an ET1-
induced subcortical stroke model, MHCII microglia in remote WM were not detectable by 
[18F]FEPPA PET or TSPO immunohistochemistry. 
The cerebellum was found to be an appropriate pseudoreference region. Other rodent AD 
studies have shown that the cerebellum is an acceptable pseudoreference region by demonstrating 
a lack of group effect on SUV [25]. When multiple pseudoreference regions are assessed in stroke, 
if the group effect is null for multiple regions, preference is sometimes given to the region with 
the lowest uptake [26]. Although SUV was lower in the periaqueductal gray and region 
contralateral to the infarct, we found that calculating UR using the cerebellum provided better 
correlations with TSPO immunohistochemistry and between DV and DVR. Using the cerebellum 
also ensured that our WM ROIs are sufficiently distant, thereby minimizing bias caused by partial 
volume effects. All of this suggests that the cerebellum is a practical pseudoreference for rodent 
TSPO PET studies of stroke and AD, but others should continue to investigate and validate their 
choice. 
Although an increase in uptake of TSPO tracers in the infarct has been well documented, 
to our knowledge, rodent studies have only investigated cortical strokes as opposed to subcortical 
strokes [20,23,24,26]. In our study, we found that ET1-induced subcortical stroke infarcts have 
increased TSPO uptake at days 7 and 28 post-stroke. The proportion of TSPO signal from 




GFAP-positive astrocyte scar between days 7 and 28 suggests a change in astrocyte function that 
might explain why in other studies, TSPO expression tends to increase in astrocytes with time after 
a stroke [20,23,24]. Similarly, microglial functions seem to change as proinflammatory markers 
differ longitudinally; after day 7, some proinflammatory markers decrease while others, including 
iNOS, increase [27]. Our study similarly demonstrated that after day 7, iNOS increased while 
TSPO decreased, albeit insignificant partly due to high variability in rodent post-stroke iNOS 
expression [28]. For these reasons, TSPO PET may not provide unequivocal, longitudinal 
measurements for guiding subject-specific infarct-targeted anti-inflammatory therapy after stroke 
in rodent models. 
Our findings suggest that TSPO does not capture diffuse WM inflammation in the 
TgAPP21 model or remote WM inflammation in the ET1-induced subcortical stroke model. WM 
TSPO studies in rodents have been restricted to mouse models of multiple sclerosis, which have 
focally elevated TSPO in active demyelinating lesions [29]. In the current study, prodromal AD 
TgAPP21 rats did not take up more [18F]FEPPA in WM, despite having previously demonstrated 
diffuse WM MHCII activated microglia [12]. Similarly, in ET1-induced subcortical stroke, WM 
TSPO expression was only increased in regions with focal inflammation and not in regions with 
diffuse inflammation. To our knowledge, TSPO overexpression in rodent WM without a nearby 
lesion has yet to be demonstrated. 
TSPO mismatch with MHCII might be dependent on whether the pathology is associated 
with antigens that would induce the antigen-presenting function of MHCII in microglia. When 
antigens are not expected to induce pathology, TSPO is overexpressed without MHCII, as was 
shown in a rat model of alcohol-induced neurodegeneration [30]. Conversely, when lesions are 




tissue had a 6-fold increase in MHCII and 2-fold increase in TSPO relative to controls [22]. Our 
work in rats demonstrates that although TSPO detected neuroinflammation near the ET1-induced 
infarct, only MHCII was able to detect the WM microglial activation that occurred late post-stroke 
or in response to overexpression of pathogenic APP. Although this makes MHCII a desirable target 
for PET, its many genetic variants may pose a challenge. 
This study has two main limitations. First, rat WM is small and susceptible to limits in PET 
resolution and sensitivity. To overcome this limitation, we used TSPO immunohistochemistry in 
rats injected with ET1 or saline to validate that TSPO is not sensitive to WM MHCII activated 
microglia. Second, this study used only males to minimize variables as females differ in their 
TSPO expression and neuroinflammatory response [31]. Whether males and females differ in their 
TSPO expression at an infarct or in WM should be further investigated.  
In conclusion, we found that an ET1-induced subcortical stroke increases TSPO 
expression. More importantly, WM microglia only expressed TSPO near an ET1-induced lesion, 
thereby revealing that TSPO was insensitive to MHCII activated microglia in remote WM and in 
WM of prodromal AD rats without a lesion. An MHCII radiotracer would enable longitudinal 
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Chapter 3: Conclusion and Future Directions 
3.1 Summary 
In the introduction, the importance of WM in neuronal networks and the definition of inflammation 
were briefly discussed to provide background about WM inflammation, particularly WM 
microglial activation. The associations between WM disease and microglial activation in 
subcortical stroke and AD, along with their main pathologies, were also described. This was 
followed by a discussion of methods that can be used to measure WM microglial activation, with 
emphasis on TSPO-PET as the focus of this thesis. Importantly, the current thesis was motivated 
by the longitudinal ability of TSPO to mark microglial activation and our findings of cognitive 
impairment along with chronic microglial activation as detected my MHCII IHC in rat models of 
subcortical stroke and prodromal AD.   
Our objectives and findings were: 
1. Objective: To investigate WM microglial activation in a rat model of prodromal AD with 
TSPO-PET using the 2nd generation TSPO-PET radiotracer, [18F]FEPPA. 
Finding: TSPO expression, as measured by [18F]FEPPA uptake ratio to cerebellum, was not 
elevated in the corpus callosum or forceps minor of a Fischer 344 rat mutated to overexpress 
a pathogenetic form of APP. 
2. Objective: To investigate WM microglial activation longitudinally in a rat model of 
subcortical stroke with TSPO-PET. 
Finding: TSPO expression, as measured by [18F]FEPPA uptake ratio to cerebellum, was not 
elevated in the corpus callosum or forceps minor of a Fischer 344 rat with subcortical stroke 




3. Objective: To investigate and validate WM TSPO expression in a rat model of subcortical 
stroke at 7-days and 28-days using IHC. 
Finding: TSPO expression at 7-days and 28-days post-stroke, as measured by cell counting on 
IHC, was not elevated in the corpus callosum or forceps minor of a Fischer 344 rat with 
subcortical stroke induced in the dorsal striatum by injection with the vasoconstrictor 
endothelin-1.  
4. Objective: To investigate WM microglial activation in a rat model of subcortical stroke using 
MHCII, iNOS, and GFAP IHC at 7-days and 28-days post-stroke. 
Finding: The only elevated percent area measurement was that of MHCII at 28-days post-
stroke in corpus callosum and forceps minor that were remote from the stroke site in a Fischer 
344 rat with subcortical stroke induced in the dorsal striatum by injection with the 
vasoconstrictor endothelin-1. 
5. Objective: To compare TSPO-PET and TSPO IHC to MHCII IHC in WM. 
Finding: In a Fischer 344 rat model of subcortical stroke by endothelin-1, MHCII IHC showed 
chronic (28-days post-stroke) diffuse WM microglial activation in remote corpus callosum 
while TSPO-PET and TSPO IHC only showed WM microglial activation that was acute (7-
days post-stroke) and proximal to a lesion. 
The implications of these findings were discussed amongst others in chapter 2, but the main 
finding was that TSPO expression was not able to detect the chronic microglial activation in WM 
that is detectable by MHCII IHC. The implications of this finding are further discussed in the 




3.2 TSPO in WM 
Despite differences in TSPO expression between rats and humans, our findings may offer insight 
into studies investigating WM microglial activation with TSPO PET in human AD and subcortical 
stroke. In particular, our finding that TSPO was only overexpressed in the infarct and in WM near 
the infarct may help explain the disagreement between human AD studies. For example, a study 
by Kreisl et al. showed that WM TSPO uptake was similar between healthy controls, patients with 
mild cognitive impairment, and AD but did not report lesions [1]. Conversely, a study by Suridjan 
et al. showed higher TSPO uptake in AD patients with lesions [2]. It is therefore possible that the 
disagreement may be attributed to the presence of lesions. Furthermore, the current findings may 
help explain why after subcortical stroke, remote WM uptake of the TSPO radiotracer 
[11C]PK11195 was elevated in patients with an infarct directly in the pyramidal tract while it was 
unaffected in patients with an infarct near a WM tract [3]. It is possible that the former induces a 
WM lesion by Wallerian degeneration with a severe inflammatory response and TSPO expression 
while the latter may not induce a lesion but, as we demonstrated in rats, it induces a delayed MHCII 
microglial activation with no TSPO expression. This cannot be confirmed as these patients were 
only tested for motor function and followed for 6 months after a stroke, however, the effects of 
subcortical stroke on cognitive impairment and dementia usually appear years later [4]. Overall, 
our findings suggest that the disagreement between human AD studies investigating WM 
microglial activation with TSPO-PET may be explained by the presence of lesions and that 
subcortical strokes that are not directly in a WM tract may not show WM microglial activation on 





3.3 MHCII as a Marker of Microglial Activation 
Although MHCII can be elevated in lesions, it can also be expressed without lesions. An example 
of a lesion where an elevated expression of MHCII has been often observed is senile plaques in 
people with AD [5]. On the other hand, non-lesion nonhuman primate studies where variation and 
risk factor factors were minimized demonstrated that the expression of MHCII increases with 
aging [6]. More recently, studies have shown that MHCII expression increases with aging 
specifically in the WM [7]. Overall, the expression of MHCII near senile plaques in people with 
AD, their increase with aging, and their increase with aging in WM suggest MHCII expression 
does not discriminate based on the presence of a lesion. 
3.4 Limitations 
3.4.1 Fischer 344 rat strain may have an overactive inflammatory response 
An additional limitation of the study was the exclusive usage of the Fischer 344 rat strain, which 
may have an overactive chronic inflammatory response. Relative to the Sprague Dawley and Lewis 
rat strains, the Fischer 344 rats have a minimal ability to habituate; when Fischer 344 rats are 
repeatedly exposed to a stress, their stress response does not decrease in magnitude [8]. 
Additionally, a low habituation corresponds to an overactive chronic inflammatory response [9]. 
It is therefore possible that Fischer 344 rats have an overactive inflammatory response. Although 
other rat models may have a reduced MHCII microglial activation response to stroke or a TgAPP21 
genotype, it is well known that MHCII microglial activation can be seen in human AD [5,7]. This 
suggests that human MHCII microglial activation may be modeled well by Fischer 344 rats. 
3.4.2 Gray Matter in Subcortical Stroke and AD 
Although there may be interest in the clinical importance of inflammation in the gray matter, we 




we therefore did not analyze all available gray matter regions using [18F]FEPPA PET. To our 
knowledge, clinical studies of subcortical stroke have not reported microglial activation in gray 
matter outside the infarct site [3]. Similarly, clinical studies of AD only report brain microglial 
activation at sites of amyloid deposition, which are restricted to the neocortex and hippocampus 
[5,10–14]. For our models, we do not expect significant inflammatory effects in the gray matter 
because we observed, using immunohistochemistry, that (i) MHCII expression was much greater 
in the white matter regions than the gray matter regions and (ii) TSPO expression was not elevated 
in gray matter, except for at the injection site in some rats (data not shown). Specifically for the 
subcortical stroke model, this is in concordance with the clinical literature and our previous 
findings that a rat subcortical stroke does not lead to microglial overactivation in remote gray 
matter, although the stroke was thalamic instead of striatal [15]. As for the AD model, our current 
observations agree with our previous studies and make sense because the model is known to not 
deposit amyloid unless there is severe cerebral stress such as encephalitis [16–18]. Because we did 
not observe any gray matter inflammation previously in extensive studies or in the 
immunohistochemistry of this study, in vivo segmentation of gray matter was omitted from our 
methods and therefore analysis.  
3.5 Future Directions 
3.5.1 MHCII radiotracers 
As stated in chapter 2, a future direction to pursue is the development of MHCII radiotracers, but 
this comes with challenges. To make accurate statements about MHCII molecules, a brief review 
of MHC nomenclature is necessary. The term MHC comes from George Davis Snell’s discovery 
that the success of tissue transplants depends on genetically-determined histocompatibility [19]. 




what the peer-reviewed literature now refers to as the MHC, which in humans has 224 genes [20]. 
These MHC genes include those that encode for three distinct classes of immune molecules: MHCI 
for innate immunity, MHCII for adaptive immunity, and MHCIII for other molecules with a 
variety of functions (Fig. 3.1). While MHCIII gene products are only referred to as molecules, 
MHCI and MHCII gene products are interchangeably referred to as molecules and glycoproteins 
because the finished proteins have many complex carbohydrates groups [21]. MHC nomenclature 
is further complicated by how MHC, MHCI, MHCII, and MHCIII are only hypernyms. For 
example, MHC molecules in humans and rats are referred to as human leukocyte antigens (HLA) 
and RT1 (no full form) respectively [22] (Fig. 3.1). Overall, these facts suggest that care is required 
when referring to the MHC or its molecules. 
Fig 3.1 A visual summary of MHC nomenclature. MHC refers to the gene complex containing 
genes that encode the protein components of the three molecule classes: MHCI, MHCII, and 
MHCIII. Each of these classes has many molecules, which may be individually named according 
to the species (HLA in humans) for a variety of other reasons 
With some genes in the MHC having over 500 alleles, the MHC is the most polymorphic 
region with phenotypic consequences in vertebrates [23]. In fact, the literature recognizes over 479 
MHC-related traits [24]. This is largely thought to have evolved for the sake of maintaining a 
diverse set of immune responses in populations [23]. On the other hand, some of these traits include 




type 1 diabetes mellitus, and AD [24,25]. In other words, although genetic mutations in the MHC 
may have led to a stronger immunity and population survival, many mutations led to disease. 
Differences in MHCII genes and molecular expression are pathologically important. For 
example, some MHCII genes are associated with disease; over 90% of human autoimmune 
diseases are associated with the presence of these three MHCII allele combinations: HLA-
DQ2/DR3, HLA-DQ6/DR2, and HLA-DQ8/DR4 [26]. Differences in molecular expression of 
MHCII have been observed in a variety of neurological pathologies, including schizophrenia, 
multiple sclerosis, multiple system atrophy, neuromyelitis optica, myasthenia gravis, Parkinson’s 
disease, and AD [27–30]. Overall, MHCII molecules are a compelling target for the quantification 
of differences because of the association between MHCII expression and neurodegenerative 
diseases, and the occurrence of autoimmune diseases in people with specific MHCII gene 
combinations. 
Although the polymorphism of MHCII poses a challenge, there may be representative 
targets without polymorphism. The polymorphism poses a challenge because differences in protein 
structure could make it unlikely for radioligands to bind every structure with a high enough affinity 
for PET imaging. Instead, there are representative targets without polymorphism including (i) the 
alpha chains in MHCII molecules, which are made up of an alpha chain and beta chain, (ii) the 
gamma chain, which transiently associates with many MHCII molecules during their folding and 
transport [20]. The alpha chain of HLA-DR is an exciting candidate because the alpha chain 
structure has been elucidated by high-resolution X-ray-crystallography (search on Uniprot, ID: 
P01903), there are several molecules known to interact with the alpha chain (also Uniprot), the 
sequence identity of humans has a 77% match with that of rats (Fig. 3.2), and HLA-DR indicates 




hinder radioligand binding, but there are alternative exciting targets with minimal or no 
polymorphism such as the HLA-DR alpha chain. 
 
Fig 3.2 HLA-DR alpha chain alignment between humans and rats. The human HLA-DR alpha 
subunit has an identical 77% match with the laboratory rat species, Rattus norvegicus.  The human 
HLA-DR alpha subunit, P01903, was set as a query with the algorithm set to search for the top 
1000 matches on the NCBI blast website protein-protein (blast.ncbi.nlm.nih.gov). One of the 
matches, here shown as “Sbjct”, was the rat variant. The numbers flanking each row indicate the 
count of the amino acid. The middle row indicates the matching results: identical matches are 
echoed, non-matches are blank, and non-matches that are chemically similar are indicated with a 
positive sign positive (+) 
 
3.5.2 Alzheimer’s Disease and Subcortical Stroke Comorbidity 
Another direction to pursue is the comorbidity of subcortical stroke and AD because it increases 
the occurrence of dementia and, potentially, WM microglial activation. A heightened dementia 




demonstrated that a dementia diagnosis was not independently increased by the presence of brain 
infarcts, but the prevalence of dementia in those with AD pathology increased from 57% to 93% 
if they also had a subcortical infarct [31]. A recent hypothesis-generating paper has attributed this 
interaction to persistent post-stroke WM microglial activation as detected by [11C]PK11195-PET 
[3]. Overall, the nun study findings of increased dementia when AD neuropathology is combined 
with subcortical stroke and the attribution of cognitive decline to WM microglial activation suggest 
that the comorbidity is a worthwhile direction to investigate.  
Despite the increased occurrence of dementia when AD pathology is combined with 
subcortical stroke, very few large studies distinguish subcortical stroke from overall stroke [32,33]. 
These large studies will be necessary to gain a more representative understanding of their 
comorbidity.  
3.5.3 Using PET to Guide WM Microglial Activation Therapy 
TSPO-PET and, if developed, MHCII-PET, may be used to guide therapeutics that target 
microglial activation. PET is powerful in this regard because it allows microglial activation to be 
imaged longitudinally and in living people. By doing so, investigators can determine if therapeutics 
have an effect on microglial activation in WM of living people, the optimal dose, and whether the 
therapeutics have an optimal therapeutic window. For example, in AD, cholinesterase inhibitors 
such as Donepezil have been shown to be beneficial only when AD is mild or moderate [34]. In 
ischemic stroke, the field has recently been able to use in vivo imaging techniques, specifically 
diffusion-weighted MRI and perfusion CT, to extend the therapeutic window to 24 hours for which 
thrombectomy is beneficial [35]. By targeting WM microglial activation instead, it may be possible 




In particular, an MHCII radiotracer would be able to guide therapeutic approaches that 
target WM MHCII microglial activation for AD and chronic timepoints after subcortical stroke. It 
may also be used to guide therapeutics for some of the other neurodegenerative diseases that, as 
mentioned in a previous section, are associated with abnormal MHCII expression such as multiple 
sclerosis. Although TSPO-PET may not be able to guide therapeutics that target MHCII microglial 
activation, it may still be used to guide other types of microglial activation. For example, TSPO-
PET was certainly able to detect the microglial and astrocyte activation that occured in the infarct 
of the subcortical stroke. 
3.6 Conclusion 
The most significant finding of this study was that TSPO was unable to mark important 
pathology in the WM in rat models of subcortical stroke and AD. Because of this important 
finding, there is a strong case to be made for the development of MHCII radiotracers. One 
promising MHCII radiotracer target might be the MHCII HLA-DR alpha chain. If developed, it 
may be able to guide therapeutic approaches targeting WM inflammation. Furthermore, TSPO-
PET may be used to guide therapeutic approaches that target the microglial and astrocyte 
activation that occurs in the infarct of the subcortical stroke. Additionally, TSPO-PET may also 
be used to image WM microglial activation that occurs after subcortical stroke that occurs 
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Appendix A: Example Logan Solution 
The Logan solution for a 2TCM may be derived using the equation defining the compartments in 
a tissue region as measured on pet (Eq1a), its integration (Eq1b), and the first-order kinetic 
equations for the exchange of radiotracer in the nondisplaceable compartment (Eq2) and bound 
compartment (Eq3). 
Eq 1a:             𝐶𝑇(𝑡) = 𝐶1(𝑡) + 𝐶2(𝑡) + 𝑉𝑏𝐶 𝐵(𝑡)              
Eq 1b:                     ∫ 𝐶𝑇(𝑢)
𝑡
0
𝑑𝑢 = ∫ 𝐶1(𝑢)
𝑡
0
𝑑𝑢 +  ∫ 𝐶2(𝑢)
𝑡
0




Eq 2:             
𝑑𝐶1(𝑡)
𝑑𝑡
=  𝐾1𝐶𝑝(𝑡) −  𝑘2𝐶1(𝑡) −  𝑘3𝐶1(𝑡) +  𝑘4𝐶2(𝑡)  
Eq 3:                 
𝑑𝐶2(𝑡)
𝑑𝑡
=  𝑘3𝐶1(𝑡) − 𝑘4𝐶2(𝑡)  








𝐶𝑇 = Concentration of total radioactivity in the tissue 
𝐶𝑝 = Concentration of free parent metabolite in the plasma 
𝐶𝑏 = Concentration of total radioactivity in whole blood 
𝐶1 = Concentration of parent metabolite in the nondisplaceable compartment 
𝐶2 = Concentration of parent metabolite in the bound compartment 
𝑉𝑏 = The ROI volume fraction of vascular tissue 
𝐾1 = plasma-to-unbound-compartment transfer rate (delivery) 




𝑘3 = unbound-compartment-to-bound-compartment transfer rate (binding) 
𝑘4 = bound-compartment-to-unbound-compartment transfer rate (unbinding) 
The approach here is to express the integrals in equation 1b in terms of known variables. To do 




𝑑𝑢, differentiate equation 1a, substitute in equations 2 and 3 and simplify, integrate, 



































[𝐾1 ∫ 𝐶𝑝(𝑢)𝑑𝑢 
𝑡
0







𝑑𝑢, integrate equation 3 then rearrange: 
𝐶2(𝑡) = ∫ 𝑘3𝐶1(𝑢)𝑑𝑢 − 
𝑡
0





























[𝐾1 ∫ 𝐶𝑝(𝑢)𝑑𝑢 
𝑡
0
− 𝐶𝑇(𝑡)  + 𝑉𝑏 ∫ 𝐶𝐵(𝑢)𝑑𝑢 
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[𝐾1 ∫ 𝐶𝑝(𝑢)𝑑𝑢 
𝑡
0
− 𝐶𝑇(𝑡)  + 𝑉𝑏 ∫ 𝐶𝐵(𝑢)𝑑𝑢 
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Appendix B: Time-activity curves 
 
Figure A.1. Time-activity curves. Representative day-28 post-stroke ET1 rat time-activity curves. 
The top row shows the initial phase with its time = 0 s equating to 27 s of the dynamic scan. The 
bottom row shows the full dynamic scan. Time-activity curves of the input function from the cavity 
of the left ventricle were corrected for the fraction of parent radiotracer that was free in the plasma. 
c, contralateral; CC, corpus callosum; CIR, contralateral to the infarct region, FM: Forceps Minor; 
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